Our patented technology – open flow microperfusion (OFM) –
is applicable in different target tissues:
dermal tissue (dOFM), adipose tissue (aOFM), and cerebral tissue (cOFM)
We perform preclinical ex-vivo and in-vivo studies as well as clinical studies and investigate
pharmacokinetics (PK) and pharmacodynamics (PD) of new drugs and bioequivalence (BE) of new pharmaceutical formulations at the target tissue level.
Using our dOFM technology, we design customized test set-ups to generate reliable data as early as possible in drug development.
cOFM technology allows a look beyond the blood-brain barrier (BBB) and assesses concentrations and effects of neuroactive substances in the targeted brain tissue.
We plan and perform studies to evaluate the bioequivalence for topical dermal generics directly in the dermis using a pharmacokinetics approach with dOFM.
aOFM technology is used to monitor drug distribution and drug-tissue interaction after subcutaneous injection by providing direct access to the interstitial fluid.
